Document Detail

In vitro predictors of clinical response in patients receiving interleukin-2-based immunotherapy.
MedLine Citation:
PMID:  8305539     Owner:  NLM     Status:  MEDLINE    
Treatment of cancer patients with interleukin-2 has resulted in clinical regression of metastatic disease. The ability to predict which patients will respond to therapy could result in more efficacious and possibly less toxic treatments. Hence, attempts have been made to correlate patient parameters or in vitro characteristics with clinical response to immunotherapy. Some patient factors have been identified as prognostically favorable. However, parameters modulated by interleukin-2 have not been predictive of clinical outcome. Exciting new evidence does exist regarding in vitro characteristics of tumor-infiltrating lymphocytes. Measurement of the cytolytic ability of melanoma tumor-infiltrating lymphocytes may enhance our understanding of the immune-mediated antitumor response and lead to a new generation of selective immunotherapies.
D J Schwartzentruber
Related Documents :
24696599 - Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insig...
3586679 - Subungual melanoma: a 25-year review of cases.
15570199 - One hundred consecutive isolated limb perfusions with tnf-alpha and melphalan in melano...
23934459 - The preliminary experience in simultaneous treatment of rectal cancer and synchronous l...
23559319 - Management of synchronous colorectal liver metastases.
25061319 - A single-institution experience with bevacizumab in the treatment of metastatic colorec...
15003889 - Gimema all - rescue 97: a salvage strategy for primary refractory or relapsed adult acu...
3972659 - Postoperative vaginal radiation in endometrial cancer using a remote afterloading techn...
25487679 - Integrin genetic variants and stage-specific tumor recurrence in patients with stage ii...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in oncology     Volume:  5     ISSN:  1040-8746     ISO Abbreviation:  Curr Opin Oncol     Publication Date:  1993 Nov 
Date Detail:
Created Date:  1994-03-16     Completed Date:  1994-03-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9007265     Medline TA:  Curr Opin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1055-8     Citation Subset:  IM    
National Cancer Institute, Bethesda, Maryland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carcinoma, Renal Cell / therapy*
Clinical Trials as Topic
Interleukin-2 / therapeutic use*
Kidney Neoplasms / therapy*
Melanoma / therapy*
Predictive Value of Tests
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cellular therapy.
Next Document:  Retinoids.